Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

SalvaRx

SalvaRx
2015 FOUNDED
PUBLIC STATUS
SALV STOCK SYMBOL
2 INVESTMENTS
Description

Provider of drug development services intended to focus on immune-oncology therapies. The company's activities include research and development of drugs and other related pharmaceutical products, enabling pharmaceutical companies to assemble and develop a portfolio of differentiated immune-oncology therapies for the treatment of late-stage cancers.

Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Stock Exchange
LON
Primary Office
  • Commerce House
  • 1 Bowring Road
  • Ramsey IM8 2LQ
  • Isle of Man, United Kingdom

SalvaRx Financials Summary

In Thousands,
USD
TTM
31-Dec-2016
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
EBITDA (3,101) (3,101) (595)
Public Fundamental Data provided by Morningstar, Inc. disclaimer

SalvaRx Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore SalvaRx‘s full profile, request access.

Request full access to PitchBook

SalvaRx Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000 20-Mar-2016 000000000000000000 Energy Exploration
iOx Therapeutics Merger/Acquisition Drug Discovery
To view this company’s complete investment and acquisition history, request access »

SalvaRx Executive Team (5)

Name Title Board
Seat
Contact
Info
Ian Walters MD Co-Founder, Chief Executive Officer & Executive Director
Robert Kramer Ph.D Co-Founder & Chief Scientific Officer
Jim Mellon Non-Executive Chairman
Denham Eke Chief Financial Officer & Director

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »

SalvaRx Board Members (1)

Name Representing Role Since Contact
Info
000 000000 SalvaRx Non-Executive Chairman 000 0000